You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,186,392


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,186,392
Title:Combination therapy
Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
Inventor(s): Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:13/695,492
Patent Claims:1. A method for maintaining a subject in a state of reduced weight after weight reducing treatment, said method comprising administering linagliptin to said subject, wherein the administration of linagliptin is carried out subsequent to the weight reducing treatment in order to maintain the reduced body weight or delay an increase in body weight in said subject.

2. The method according to claim 1, wherein the weight reducing treatment is selected from diet, exercise and/or treatment with an anti-obesity or weight reducing agent selected from the group consisting of a glucagon-like peptide-1 (GLP-1) receptor agonist, a lipase inhibitor which is orlistat or cetilistat, a cannabinoid receptor 1 antagonist, a melanocortin-4 (MC4) receptor agonist, a neuropeptide Y2-receptor (NPY2) antagonist, a 5-hydroxytryptamine 2C (5HT2c) receptor agonist, a Ghrelin antagonist, pancreatic peptide YY3-36 (Pyy 3-36), leptin, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, a noradrenaline-dopamine-5HT reuptake inhibitor, bupropion/naltrexone, bupropion/zonisamide, topiramate/phentermine, pramlintide/metreleptin, a melanin-concentrating hormone (MCH) antagonist, a cholecystokinin (CCK) inhibitor, a fatty acid synthase (FAS) inhibitor, an acetyl-CoA carboxylase (ACC) inhibitor, a stearoyl-CoA desaturase (SCD) inhibitor, a beta3 adrenoreceptor agonist, a microsomal triglyceride transfer protein (MTP) inhibitor, and amylin or an amylin analogue which is davalintide or pramlintide.

3. The method of claim 1, wherein the subject is an obesity patient prior to weight reducing treatment.

4. A method for maintaining a subject in a state of reduced weight after weight reducing treatment with a GLP-1 receptor agonist selected from exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide and dulaglutide, said method comprising administering linagliptin to said subject wherein the administration of linagliptin is carried out subsequent to the weight reducing treatment with said GLP-1 receptor agonist in order to maintain the reduced body weight or delay an increase in body weight in said subject.

Details for Patent 9,186,392

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amryt Pharmaceuticals Dac MYALEPT metreleptin For Injection 125390 02/24/2014 ⤷  Try a Trial 2030-05-05
Glaxosmithkline Llc TANZEUM albiglutide For Injection 125431 04/15/2014 ⤷  Try a Trial 2030-05-05
Eli Lilly And Company TRULICITY dulaglutide Injection 125469 09/18/2014 ⤷  Try a Trial 2030-05-05
Eli Lilly And Company TRULICITY dulaglutide Injection 125469 09/04/2020 ⤷  Try a Trial 2030-05-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.